论文部分内容阅读
[目的]检测肺癌组织中LyGDI的mRNA和蛋白表达水平及其与临床参数的关系。[方法]运用逆转录—聚合酶链反应技术(RT-PCR)和Western blot免疫蛋白印迹法检测39例肺癌组织及其癌旁组织和正常肺组织中LyGD的mRNA和蛋白表达水平,并分析其与临床病理参数的关系。[结果]RT-PCR结果显示75.7%(28/37)肺癌组织中LyGDI的mRNA和蛋白表达水平显著高于癌旁肺组织。表达量的差异有统计学意义。在癌旁组织与正常肺组织表达接近。免疫蛋白印迹法检测结果与RT-PCR一致。[结论]LyGDI在肺癌组织中的高表达可能是肿瘤发生过程中的一个重要因素,其表达的蛋白产物可作为临床上肺癌诊断和治疗的一个重要指标。
[Objective] To detect LyGDI mRNA and protein expression in lung cancer and its relationship with clinical parameters. [Methods] LyGD mRNA and protein expression levels in 39 lung cancer tissues, adjacent non-cancerous tissues and normal lung tissues were detected by reverse transcription-polymerase chain reaction (RT-PCR) and Western blotting. And clinicopathological parameters. [Result] The results of RT-PCR showed that the mRNA and protein expressions of LyGDI in 75.7% (28/37) lung cancer tissues were significantly higher than those in adjacent lung tissues. There was significant difference in expression level. In adjacent tissues and normal lung tissue expression close. Immunoblotting assay results were consistent with RT-PCR. [Conclusion] The high expression of LyGDI in lung cancer may be an important factor in tumorigenesis. The expressed protein may be used as an important index in the diagnosis and treatment of lung cancer.